You have 9 free searches left this month | for more free features.

Relapsed Non-Hodgkin Lymphoma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Duarte, Hackensack, Houston (SIRPant-M, External-beam

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • SIRPant-M
  • External-beam radiotherapy (XRT)
  • Duarte, California
  • +2 more
Jul 21, 2023

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
    • (no location specified)
    Sep 19, 2023

    Non-Hodgkin Lymphoma Trial in Taiwan, United States (CHO-H01)

    Recruiting
    • Non-Hodgkin Lymphoma
    • CHO-H01
    • The Woodlands, Texas
    • +7 more
    Jul 10, 2023

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
    • +6 more
    • (no location specified)
    Apr 12, 2023

    Refractory or Relapsed Non-Hodgkin's Lymphoma Trial in Nice (blood samples and 18FDG PET-CT exams)

    Not yet recruiting
    • Refractory or Relapsed Non-Hodgkin's Lymphoma
    • blood samples and 18FDG PET-CT exams
    • Nice, France
      CHU de Nice
    Jun 20, 2022

    CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Suzhou (ThisCART19A with Dose Level 1, ThisCART19A with Dose Level

    Recruiting
    • CAR
    • +2 more
    • ThisCART19A with Dose Level 1
    • ThisCART19A with Dose Level 2
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jan 18, 2023

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Jinan (CAR-T cells)

    Recruiting
    • Relapsed Non-Hodgkin Lymphoma
    • +2 more
    • CAR-T cells
    • Jinan, Shandong, China
      The Second People's Hospital of Shandong Province
    Jun 14, 2022

    Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)

    Not yet recruiting
    • Refractory Non-Hodgkin Lymphoma
    • Relapsed Non-Hodgkin Lymphoma
    • ARI0003
    • Santiago De Compostela, A Coruña, Spain
    • +6 more
    Oct 24, 2023

    Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma Trial in Sacramento (biological, radiation, procedure, drug)

    Active, not recruiting
    • Refractory Non Hodgkin Lymphoma
    • Relapsed Non Hodgkin Lymphoma
    • rituximab
    • +7 more
    • Sacramento, California
      University of California Davis
    Nov 28, 2022

    Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Cleveland (Loncastuximab tesirine, Venetoclax)

    Recruiting
    • Relapsed Non Hodgkin Lymphoma
    • Refractory Non-Hodgkin Lymphoma
    • Cleveland, Ohio
      Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cance
    May 20, 2022

    Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

    Not yet recruiting
    • Relapsed/Refractory Non-Hodgkin Lymphoma
    • Duarte, California
    • +1 more
    Oct 13, 2023

    Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

    Not yet recruiting
    • Non-hodgkin's Lymphoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Sep 27, 2023

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in United States (IMPT-314)

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
    • Refractory Non-Hodgkin Lymphoma
    • Los Angeles, California
    • +3 more
    Apr 12, 2023

    Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

    Not yet recruiting
    • Classical Hodgkin Lymphoma
    • Non-Hodgkin Lymphoma
    • GEN3017
    • (no location specified)
    Aug 25, 2023

    Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,

    Recruiting
    • Lymphoma, Non-Hodgkin
    • +6 more
    • CB-010
    • +2 more
    • Scottsdale, Arizona
    • +7 more
    Aug 19, 2022

    Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • CD38-SADA:177Lu-DOTA Complex
    • (no location specified)
    Aug 15, 2023

    Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Tampa (Comprehensive Ablative Bridging Irradiation (CABI),

    Recruiting
    • Large B-cell Lymphoma
    • Relapsed Non-Hodgkin Lymphoma
    • Comprehensive Ablative Bridging Irradiation (CABI)
    • Chimeric Antigen Receptor T-Cell Therapy
    • Tampa, Florida
      Moffitt Cancer Center
    Oct 26, 2023

    Non Hodgkin Lymphoma Trial in New York, Clayton, Frankston (IPH6501)

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • New York, New York
    • +2 more
    Oct 12, 2023

    Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igß

    Recruiting
    • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
    • Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Apr 3, 2022

    Non-hodgkin Lymphoma Trial (HY004)

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • HY004
    • (no location specified)
    Aug 21, 2023

    Lymphoma, Non-Hodgkin's, Adult Trial (SP-3164)

    Not yet recruiting
    • Lymphoma, Non-Hodgkin's, Adult
    • (no location specified)
    Aug 4, 2023

    Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial in Miami (Mosunetuzumab,

    Not yet recruiting
    • Refractory Non-Hodgkin Lymphoma
    • +2 more
    • Miami, Florida
      University of Miami
    Aug 3, 2022